{"id":"W2085518532","doi":"10.1016/j.ejca.2011.05.017","title":"Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial","year":2011,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Pazopanib; Placebo; Medicine; Renal cell carcinoma; Quality of life (healthcare); Oncology; Internal medicine; Clinical trial; Phases of clinical research; Alternative medicine; Sunitinib; Pathology; Nursing","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002312077,0.0002340281,0.001226405,0.000307439,0.00002663689,0.000006017121,0.0001477946,0.00003282905,0.0002770965],"category_scores_gemma":[0.0002824099,0.0001510817,0.0001600052,0.00033546,0.00006444233,0.0001332664,0.00002619505,0.0004437901,0.000002414287],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003950112,"about_ca_system_score_gemma":0.0008315782,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003875915,"about_ca_topic_score_gemma":0.000211277,"domain_scores_codex":[0.9953372,0.00136555,0.002194825,0.0002321735,0.0005548688,0.0003153567],"domain_scores_gemma":[0.9970943,0.0001452372,0.001915397,0.0002429263,0.00026779,0.000334348],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8735913,0.001610954,0.1088967,0.0001200699,0.00009735096,0.0004777107,0.003648452,0.00006807856,0.0005174854,6.07439e-7,0.00009462857,0.01087659],"study_design_scores_gemma":[0.5720099,0.008641653,0.4173722,0.0005381989,0.00006186453,0.000007910699,0.0001309963,0.000005550896,0.001096632,9.22474e-7,0.00002877832,0.0001054653],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9947243,0.001532501,0.0000244296,0.0001073284,0.0002133222,0.001322276,0.000008682044,0.000006606176,0.002060544],"genre_scores_gemma":[0.9989066,0.00008819034,0.0005906087,0.00009364472,0.00009078463,0.00001098942,0.000005524601,0.00004791695,0.0001658156],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3084755,"threshold_uncertainty_score":0.6160932,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05298764010998183,"score_gpt":0.3047085310886384,"score_spread":0.2517208909786566,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}